Evercore says Filspari inclusion in new guidelines should give Travere boost

Evercore ISI notes that new KDIGO IgAN Draft Guidelines are out for public review and points out the guidelines include the use of Filspari, or sparsentan, for the management of IgAN. The firm expects this should provide a boost to sales with guidelines now part of marketing armamentarium and with payors who often refer to guidelines for clinical formulary decisions, adding that another boost should come in a little less than a week when the firm expects the FDA to grant full approval to sparsentan based on the full Phase 3 dataset. Evercore maintains an Outperform rating and $12 price target on Travere Therapeutics shares.